At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib, Carfilzomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 84 participants across 17 sites in 2 countries.
Detailed Summary
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartDec 2013
Primary CompletionMar 2019
TodayJul 2026
First PostedOct 14, 2013
Enrollment StartDec 1, 2013
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.7 years ago
Interventions
Ibrutinibdrug
Carfilzomibdrug
Dexamethasonedrug